Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

NCT05846789 is registered in ClinicalTrials.gov with Kathy Miller as lead sponsor.

NCT NCT05846789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05846789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Lead sponsor
Kathy Miller
Phase
Phase 2
Overall status
Recruiting
Start date
July 2, 2024
Completion date
December 31, 2027
Enrollment
168 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

er positive, her2 negative breast cancer, estrogen-receptor-low breast cancer, metastatic breast cancer, triple negative breast cancer